Securities code: Hybio Pharmaceutical Co.Ltd(300199) securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022035 Hybio Pharmaceutical Co.Ltd(300199)
Announcement on applying for comprehensive credit line from banks
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as “the company”) held the fifth meeting of the Fifth Board of directors on March 24, 2022, deliberated and adopted the proposal on applying for comprehensive credit line from the bank, in order to further expand financing channels, optimize financial structure, supplement working capital and ensure the development needs of the company according to the needs of business development of the company. It is agreed that the company applies to the bank for a comprehensive credit line of no more than 300 million yuan. The specific situation is hereby announced as follows:
1. It is agreed that the company applies to Bank Of Beijing Co.Ltd(601169) Shenzhen Branch for a comprehensive credit line of no more than 50 million yuan, and the subsidiary Hybio Pharmaceutical Co.Ltd(300199) (Wuhan) Co., Ltd. provides joint and several liability guarantee. The credit term is tentatively set as 3 years. The guarantee method and final reply of this financing credit shall be subject to the actual approval of the bank.
2. It is agreed that the company applies to China Zheshang Bank Co.Ltd(601916) Shenzhen Branch for a comprehensive credit line with a total line of no more than 250 million yuan, and the credit term is tentatively set at 3 years. The guarantee method and credit line and term of this financing credit shall be subject to the actual approval of the bank.
Within the above credit line, the company and its wholly-owned subsidiaries can be recycled, and the company will use some fixed assets as collateral. The above credit line shall be subject to the actual approval of the bank, and the specific use limit will be determined within the limit approved by the bank according to the actual demand of the company’s working capital.
The above comprehensive credit extension includes but is not limited to working capital loan, project loan, financial leasing, bank acceptance bill, letter of guarantee, factoring, opening letter of credit, trade financing, bill discount and other comprehensive credit extension businesses. The single financing within the above credit line will not be reported to the board of directors for deliberation.
For the above matters of applying to the bank for a comprehensive credit line, the chairman of the company is authorized to sign relevant credit documents and authorize the management to use the above credit line according to the capital demand.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of directors March 25, 2022
